SCHEDULE 13G/A: Wellington Management Affiliates Disclose Passive Stake in Rocket Pharmaceuticals

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.93% in Rocket Pharmaceuticals, Inc.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively filed an Amendment No. 6 to Schedule 13G.
• The filing discloses their beneficial ownership of Common Stock in Rocket Pharmaceuticals, Inc. (CUSIP: 77313F106).
• As of May 30, 2025, the aggregate amount beneficially owned by the reporting persons is 1,004,476 shares.
• This represents 0.93% of the class of Rocket Pharmaceuticals, Inc. Common Stock.
• The reporting persons hold no sole voting or sole dispositive power over these shares.
• They hold shared voting power over 770,285 shares and shared dispositive power over 1,004,476 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
• The filing explicitly states that the joint filing agreement does not constitute an admission that the persons named herein form a group for purposes of Regulation 13D-G or a joint venture for purposes of the Investment Company Act of 1940.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing passive ownership, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The continued disclosure of a stake by a major investment firm like Wellington Management Group LLP indicates ongoing, albeit passive, interest in Rocket Pharmaceuticals, Inc.

Negatives

• The beneficial ownership percentage of 0.93% is a relatively small, passive stake, indicating no significant influence or control over the company.

Risks

• The document clarifies that the reporting persons are not acting as a group for control purposes, mitigating potential risks associated with activist investor groups.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding Rocket Pharmaceuticals, Inc.'s future operations or financial performance.

Industry Context

This filing is a routine disclosure of passive institutional ownership, common in the financial industry, and does not provide specific insights into broader trends within the biotechnology or pharmaceutical sectors beyond the fact that a major asset manager holds a small stake in Rocket Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no immediate intent to influence control.

Key Dates

Keywords

Rocket Pharmaceuticals, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Disclosure, Passive Investment